Crook T H, Tinklenberg J, Yesavage J, Petrie W, Nunzi M G, Massari D C
Memory Assessment Clinics, Inc., Bethesda, MD 20814.
Neurology. 1991 May;41(5):644-9. doi: 10.1212/wnl.41.5.644.
We treated 149 patients meeting criteria for age-associated memory impairment (AAMI) for 12 weeks with a formulation of phosphatidylserine (100 mg BC-PS tid) or placebo. Patients treated with the drug improved relative to those treated with placebo on performance tests related to learning and memory tasks of daily life. Analysis of clinical subgroups suggested that persons within the sample who performed at a relatively low level prior to treatment were most likely to respond to BC-PS. Within this subgroup, there was improvement on both computerized and standard neuropsychological performance tests, and also on clinical global ratings of improvement. The results suggest that the compound may be a promising candidate for treating memory loss in later life.
我们使用磷脂酰丝氨酸制剂（100毫克BC - PS，每日三次）或安慰剂对149名符合年龄相关性记忆障碍（AAMI）标准的患者进行了为期12周的治疗。与接受安慰剂治疗的患者相比，接受该药物治疗的患者在与日常生活学习和记忆任务相关的性能测试中有所改善。临床亚组分析表明，样本中治疗前表现相对较低水平的人最有可能对BC - PS有反应。在这个亚组中，计算机化和标准神经心理学性能测试以及临床总体改善评分均有改善。结果表明，该化合物可能是治疗晚年记忆力减退的一个有前景的候选药物。
